A targeted grant to support evidence-based projects focused on benefiting access to cancer clinical trials. Project must have the potential to be embedded and scaled up in the health system and are sustainable past the funding period.
Key information
- Status: Closed
- Grant amount: Up to $250,000
- Application opened: 31 May 2024
- Application closed: 14 June 2024, 10:00 am
Program objective
- Development of networks or services to improve access to clinical trials, such as early phase cancer clinical trials.
- Improve capacity and capability of the clinical trials workforce.
- Improve awareness of clinical trials in the primary care sector.
- Improve awareness and address barriers to cancer clinical trials for at least one community identified as a ‘focus population’ in the NSW Cancer Plan.
This program is funded and administered by Cancer Institute NSW.
Eligibility
Who can apply
Applicants must meet all of the follow criteria to be eligible:
- be a current chief investigators of Cancer Institute NSW
- employed at an institution within NSW for the duration of the grant.
Chief Investigators' can only be named on one Clinical Trials Support Grant application for each grant round.
Applicants must nominate a single administering institution who will be responsible for the management of the grant. This institution must:
- Have procedures and policies in place for the administration of public funds and management of intellectual property.
- Have good scientific practice and provide appropriate infrastructure to allow for research support by the grant to be undertaken.
The Administering Institution and their nominated institutional contact must be registered with the Cancer Institute NSW. Refer to the list of Registered Administering Institutions and the Administering Institution Contact Registration Form.
Who can't apply
- Researchers that are not current chief investigators of Cancer Institute NSW.
- Researchers or Chief Investigators working in organisations outside of NSW.
- Institutions that cannot provide appropriate, procedures, policies and infrastructure to support research funded by the grant.
What you can apply for
Example projects that are suitable to be funded by this grant include:
- Developing educational materials and tools to increase referrals to specialists and hospitals participating in cancer clinical trials.
- Identifying barriers and challenges in accessing clinical trials for a focus population and developing appropriate solutions.
- Identifying efficiency gaps in a clinical trial unit’s workstream and developing an appropriate tool to address the gaps.
- Co-designing appropriate resources for Aboriginal people to improve awareness of and participation in cancer clinical trials and/or the healthcare sector.
What you can't apply for
- Basic or overhead infrastructure costs (such as desks, stationary, institutional overheads or administrative levies).
- Funding to support research conducted outside of NSW.
- Development of technology platforms and programs limited to engagement.
- Costs associated with the promotion of clinical trials.
Most recent recipients
What your application needs to include
Applications must be completed on the Cancer Institute NSW Application form and include:
- Curriculum Vitae (CV) from Chief Investigator and all co-investigators
- Relevant support letters
- NSW Aboriginal Health Impact Statement (if applicable).
View the full grant guidelines. (PDF 162.07KB)
A Program Logic Model and Risk Management Plan must be submitted within 2 months after the grant is awarded.
Prepare your application with this checklist
- Curriculum Vitae (CV) from Chief Investigator and all co-investigators
- Relevant support letters
- NSW Aboriginal Health Impact Statement (if applicable).
- Program Logic Model (to be submitted within 2 months after grant is awarded)
- Risk Management Plan (to be submitted within 2 months after grant is awarded)
Address the eligibility criteria
- Located in NSW
- Chief Investigator must be a current Chief Investigator of a Cancer Institute NSW Translational Cancer Research Capacity Building Grant.
- An Administering Institution is nominated. The Administering Institution and their nominated institutional contact must be registered with the Cancer Institute NSW. Refer to the list of Registered Administering Institutions and the Administering Institution Contact Registration Form.
- Demonstrate consumer involvement, particularly with the focus population, and engagement across the development of the grant and its funding period.
Address the assessment criteria
Significance (20%)
The primary aim of the CTSG must have appropriate emphasis on at least one of the grants objectives:
- Development of networks or services to improve access to clinical trials, such as early phase cancer clinical trials
- Improve capacity and capability of the clinical trials workforce
- Improve awareness of clinical trials in primary care sector
- Improve awareness and address barriers to cancer clinical trials for at least one community identified as a ‘focus population’ in the NSW Cancer Plan. The communities who are disproportionately affected by cancer include:
- Aboriginal communities.
- Multicultural communities.
- People from lower socioeconomic backgrounds.
- Regional, rural and remote communities.
- Older people.
- Sexuality and gender diverse people (lesbian, gay, bisexual, transgender, intersex and queer people, known as LGBTIQ+ communities).
- People with a mental health condition.
- People who are engaged with the justice system.
The significance of the project should be demonstrated by:
- Addressing a major evidence-practice gap of critical importance in the cancer clinical trial sector.
- A feasible implementation plan (rationale, design, methodology) with anticipated outcomes to accomplish the aims of the grant.
- Consumer engagement throughout the entirety of the implementation program.
Scalability (20%)
The applicants must demonstrate a scalability plan to roll out initiatives to multiple sites within NSW. Considerations include:
- pathways for scaling up project findings across NSW
- likely level of adoption or uptake of project
- likely required timeframes required to achieve desired results.
Sustainability (20%)
The applicants must demonstrate that the team has a sustainability plan after the completion of the grant funding. Considerations include:
- Evidence of established strategic partnerships and stakeholder engagement strategies to ensure successful expansion.
Evaluation and Outputs (20%)
The applicant must demonstrate that the team has a plan for the evaluation of the implementation program and the resulting outcomes. Considerations include:
- a clear process for monitoring the progress of the project, including achievable key milestones and outcome indicators that can be delivered during the grant
- the potential to impact on health service improvements
- the anticipated ability to leverage future funding.
Team Track Record (20%)
The named Investigators as individuals and as a diverse research team, should demonstrate:
- A track record in managing and successfully implementing projects.
- A high degree of established collaborations amongst team members with reference to the length of collaboration and achievements.
- A clear plan on how the research team will promote and sustain a collaborative approach for the duration of the grant funding.
- Capability to undertake the proposed implementation program in the grant timeframe and to continue.
After the application is submitted
The applications will be assessed and both successful and unsuccessful applicants will be notified.
The Cancer Institute NSW will consider all recommendations for funding by the Grants Review Committee and the Chief Executive will approve funding for the grants to be awarded.